Three Markets. One Documentation Investment. The Global Regulatory Sequence That Unlocks India in 9 Months
The Approval Sequence Nobody Tells You About — How Getting UK Approval First Can Unlock the Fastest India Regulatory Pathway
By Ankur Khare — Biomedical Engineer | Regulatory Affairs Specialist | Founder, MedReg Intel
Most overseas medical device manufacturers think about India regulatory strategy in isolation.
They ask their Indian regulatory consultant: what do we need to enter India? The consultant says: CE marking or FDA clearance triggers Rule 36(3), which eliminates clinical investigation.
Or: you need to conduct clinical investigation in India.
Or: find an Indian predicate and file MD-14 under Rule 51(5).
All of these answers are correct. None of them are complete.
Because the most important regulatory decision for an overseas manufacturer entering India is often not made in India at all. It is made in the sequence of global regulatory approvals they choose to pursue — and specifically in whether they understand how that sequence can be engineered to unlock the fastest possible India pathway as a consequence of approvals they were pursuing anyway.
This article is about that sequence.
Specifically it is about why obtaining UK approval under UKCA first — before pursuing FDA clearance or full EU MDR CE marking — can be the single most commercially intelligent regulatory sequencing decision an overseas manufacturer makes. Not because of the UK market. But because of what the UKCA approval enables in India.
The India Regulatory Context You Already Know
If you have been following MedReg Intel you already know the foundation.
Rule 36(3) of MDR 2017 eliminates the clinical investigation requirement for devices holding free sale certificates from Australia, Canada, Japan, EU Countries, or the United States of America. The rule is drafted in mandatory language. If a valid free sale certificate from a qualifying jurisdiction exists the clinical investigation requirement is gone.
The qualifying document is a free sale certificate from a national regulatory authority of an EU member state — not the CE certificate from a Notified Body. Germany's BfArM. Netherlands' IGJ. France's ANSM.
The pathway from CE marking with EU free sale certificate to Indian import licence is nine months from a complete MD-14 application. The pathway without it — through clinical investigation — extends over multiple years.
That is the foundation. Now comes the sequencing insight built on top of it.
The UKCA Framework — What It Is and Why It Matters
When the United Kingdom left the European Union, UK-placed medical devices could no longer rely on CE marking for market access. The UK developed its own conformity assessment framework — UKCA marking — administered by the Medicines and Healthcare products Regulatory Agency, MHRA.
UKCA has several characteristics that make it strategically interesting for manufacturers thinking about global regulatory sequencing.
The technical documentation overlap with CE marking is substantial.
EU MDR 2017/745 and the UK's medical device regulations share a common heritage — UK regulations were derived from EU directives before Brexit. The technical documentation required for UKCA and for CE marking under EU MDR 2017/745 covers substantially the same ground.
General Safety and Performance Requirements equivalent. Clinical evaluation or clinical investigation data. Quality management system documentation. Risk management file under ISO 14971. Post-market surveillance plan. Technical file or Design Dossier.
A manufacturer who has prepared documentation for UKCA has done the majority of the technical work required for CE marking under EU MDR 2017/745. The delta — what needs to be added or adapted to convert UKCA-ready documentation to CE-ready documentation — is real but significantly smaller than building a CE submission from scratch.
The UKCA pathway for many device categories is faster than FDA.
This is a generalisation with important exceptions — but it reflects the practical experience of many manufacturers navigating global regulatory pathways simultaneously.
FDA 510(k) processing times have extended significantly. FDA PMA timelines are measured in years. De Novo classifications add complexity and uncertainty.
UKCA assessments for Class IIa and IIb devices — the UK equivalents of CE Class IIa and IIb — have in many categories been processed with reasonable efficiency by MHRA-approved UK Approved Bodies.
For a manufacturer comparing UK versus US as their first major regulatory milestone on the path to India — the UKCA pathway may reach the milestone faster for many device categories.
UKCA approval alone does not trigger Rule 36(3).
This is the critical constraint that makes the sequencing question interesting.
As discussed in the Rule 36(3) article — the UK is not on the Rule 36(3) reference list. Since Brexit the UK is no longer an EU country for the purposes of that provision. A UKCA-only approval does not give you a free sale certificate from an EU national competent authority. It does not trigger Rule 36(3).
This is exactly why the sequencing insight matters.
The Three-Step Sequence
The regulatory sequence that unlocks the fastest India pathway through UKCA looks like this.
Step 1 — UKCA approval
The manufacturer pursues UKCA approval first. Reasons: faster timeline than FDA for many device categories, UK market access has commercial value, and UKCA technical documentation preparation does most of the work required for the next step.
Timeline depends on device class and complexity. Class IIa devices — UK equivalent of EU Class IIa — can often be assessed within 3 to 9 months by a UK Approved Body once documentation is complete.
Step 2 — CE marking using UKCA-ready documentation
The manufacturer uses the technical documentation developed for UKCA as the foundation for their EU MDR 2017/745 CE marking application. Because the documentation overlap is substantial the additional work required to reach CE marking is significantly less than starting from scratch.
CE marking under EU MDR 2017/745 requires a Notified Body — a conformity assessment body accredited under EU MDR — to assess the technical documentation and quality management system. The Notified Body issues a CE certificate. The manufacturer then obtains a free sale certificate from a national competent authority of an EU member state — BfArM in Germany, IGJ in Netherlands, ANSM in France.
This free sale certificate is the qualifying document for Rule 36(3) in India.
Step 3 — MD-14 application under Rule 36(3)
With the EU national competent authority free sale certificate in hand the manufacturer files an MD-14 import licence application to CDSCO citing Rule 36(3).
Clinical investigation requirement — eliminated. Decision timeline — nine months from complete application under Rule 36(1). Market — India's USD 11 billion and growing medical device market.
Why This Sequence Is Superior to the Alternatives
To understand why the UKCA-first sequence is strategically valuable it helps to compare it explicitly to the alternatives.
Alternative 1 — FDA first, then CE, then India
This is the default sequence for most US-origin or US-focused manufacturers. FDA clearance or approval is pursued first because the US market is the primary commercial objective.
The challenge is that FDA timelines have extended significantly. A 510(k) submission that would have cleared in 3 months five years ago now averages 6 to 9 months. PMA applications take years. De Novo classifications add unpredictability.
For a manufacturer whose primary commercial objective is not the US market but who needs FDA clearance to trigger Rule 36(3) in India — waiting 6 to 9 months or more for FDA clearance before starting the CE marking process that then triggers India eligibility — is a sequential delay that the UKCA-first sequence eliminates.
Alternative 2 — CE marking directly, without UKCA
Pursuing CE marking under EU MDR 2017/745 directly — without UKCA as a stepping stone — is viable but has specific challenges.
EU MDR 2017/745 is significantly more demanding than the EU directives it replaced. The clinical evidence requirements, post-market surveillance obligations, and technical documentation standards under EU MDR are substantially higher than under the previous Medical Devices Directive. Notified Body backlogs for EU MDR assessments have created extended timelines for many device categories.
The UKCA pathway — which currently operates under UK regulations that are less onerous than EU MDR 2017/745 in several respects — can reach approval faster and generate documentation that substantially satisfies EU MDR requirements. Using UKCA as the first step accelerates the path to CE marking rather than delaying it.
Alternative 3 — India clinical investigation directly
For manufacturers without reference country approval the only India pathway is clinical investigation under Chapter VII of MDR 2017 — unless a predicate device exists under Rule 51(5).
The UKCA-first sequence converts this 3 to 5 year pathway into a 9-month pathway by generating the CE marking and EU free sale certificate that triggers Rule 36(3). The time investment in UKCA and CE marking — typically 12 to 24 months for many device categories — is less than the time investment in Indian clinical investigation — and generates UK and EU market access as additional commercial outcomes.
The Commercial Logic — Three Markets, One Documentation Investment
This is the most important frame for understanding why the UKCA-first sequence is not just a regulatory tactic but a commercial strategy.
A manufacturer who follows the UKCA-first sequence ends up with:
UK market access — from UKCA approval. The UK is a significant medical device market with a sophisticated healthcare system and strong demand for quality devices.
EU market access — from CE marking. The EU is one of the world's largest medical device markets across 27 member states.
India market access — from Rule 36(3) triggered by the EU free sale certificate. The world's most populous country with a rapidly growing healthcare system.
Three major markets. One documentation investment — because UKCA documentation substantially overlaps with CE documentation which substantially overlaps with the technical file requirements for India MD-14.
The alternative — pursuing each market independently with separate regulatory strategies and separate documentation investments — costs significantly more in time, money, and management attention.
The UKCA-first sequence is regulatory pathway engineering that generates multi-market commercial outcomes from a single coordinated documentation effort.
The Timing Question — When Does This Sequence Make Sense
The UKCA-first sequence is not optimal for every manufacturer in every situation. Being honest about when it applies and when it does not is important.
It makes sense when:
The manufacturer does not yet have any major regulatory approval — no FDA clearance, no CE marking — and is making their first decisions about global regulatory sequencing.
The manufacturer's primary near-term commercial objective includes India as a significant market — not just a future consideration.
The device category has a defined UKCA pathway with reasonable assessment timelines at a UK Approved Body.
The technical documentation for UKCA can be prepared in parallel with or prior to CE marking documentation without significant additional cost.
It makes less sense when:
The manufacturer already has FDA clearance or CE marking. In this case the sequencing question has already been answered — the focus should be on obtaining the EU free sale certificate to trigger Rule 36(3) directly.
The device category has specific EU MDR requirements that are significantly more onerous than UKCA requirements — making the UKCA step provide less documentation leverage than the general analysis suggests.
The UK market is commercially irrelevant to the manufacturer and the UKCA step adds time and cost without proportionate benefit.
The manufacturer's timeline pressure means every month matters and the additional UKCA step — even if it accelerates the CE pathway — adds a sequential milestone that direct CE pursuit would avoid.
What This Means for Indian Regulatory Strategy
Most Indian regulatory consultants advise on India only. They know MDR 2017. They know CDSCO. They know the pathways within the Indian regulatory framework.
What they do not do is advise on the global regulatory sequence that determines which Indian pathway is available.
A manufacturer who arrives in India with UKCA approval and a CE certificate has already made the regulatory decisions that determine their India pathway. The Indian regulatory consultant's job is to execute the Rule 36(3) pathway efficiently.
A manufacturer who arrives in India without any major regulatory approval — asking which pathway to pursue — is at a decision point where the most valuable advice is not about MDR 2017 at all. It is about which global regulatory sequence will get them to India fastest and most efficiently.
That advice requires understanding UKCA, FDA, EU MDR, and MDR 2017 simultaneously — and thinking across them strategically rather than advising on each in isolation.
This cross-jurisdictional strategic thinking is one of the most underserved capabilities in Indian MedTech regulatory consulting. Most consultants give India advice. Very few give global sequence advice that happens to optimise the India outcome.
One Important Caveat on UKCA Current Status
Regulatory frameworks evolve. The UK has extended UKCA transition timelines multiple times since Brexit as manufacturers and the UK government navigated the practical complexities of establishing a new regulatory framework.
Before making UKCA-first sequencing decisions based on this article — verify the current UKCA transition timeline status with MHRA directly or through a UK regulatory specialist. The strategic logic of UKCA-first sequencing remains valid. The specific timelines and documentation requirements should be confirmed against current MHRA guidance rather than assumed from this analysis.
This is an important caveat because regulatory sequencing decisions made on outdated timeline assumptions can lead to outcomes that differ materially from the analysis here.
The Bottom Line
The fastest pathway to India for many overseas medical device manufacturers is not primarily an India regulatory question.
It is a global regulatory sequencing question.
UKCA approval generates UK market access and creates technical documentation that substantially overlaps with CE marking requirements. CE marking with an EU national competent authority free sale certificate triggers Rule 36(3) of MDR 2017 — eliminating the clinical investigation requirement and opening a nine-month India import licence pathway.
Three markets. One coordinated documentation investment. The India pathway unlocked as a consequence of approvals pursued for their own commercial value.
Most Indian regulatory consultants will not tell you this because they do not think across jurisdictions. Most global regulatory consultants will not tell you this because they do not know Rule 36(3).
The gap between those two expertise areas is where the most valuable regulatory advice lives.
MedReg Intel tracks regulatory developments, compliance strategy, and policy analysis relevant to India's medical device sector at medregintel.com
If you are an overseas medical device manufacturer making global regulatory sequencing decisions and want to understand how your approval sequence affects your India pathway — reach out at ankur@medregintel.com
Ankur Khare is a Biomedical Engineer and Regulatory Affairs Specialist and the founder of MedReg Intel. This article is for informational purposes and does not constitute formal regulatory or legal advice.
Comments
Post a Comment